XLRN News and Press, Acceleron Pharma Inc. From 02/27/20

Acceleron Pharma, Inc. (XLRN) Q4 2019 Earnings Conference Call February 27, 2020 5:00 PM ET Company Participants Todd James - Senior Vice President, Corporate affairs and Investor Relations Habib Dable - Chief Executive Officer Kevin McLaughlin - Chief Financial Officer Sujay K...

The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2019 Q4 earnings Read more ...

Acceleron Pharma (NASDAQ: XLRN ): Q4 GAAP EPS of -$0.44 misses by $0.09 . More news on: Acceleron Pharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- REBLOZYL ® (luspatercept-aamt), a first-in-class erythroid maturation agent, was approved by the U.S. FDA for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions; FDA review of the sBLA for the lower-risk myelodysplast...

Healthcare Pulse Source: Bloomberg The fear of Coronavirus (Covid-19) has infected the stock market. The market's patience completely ran out this week as the Coronavirus news, which has continued to weigh heavily on the negative side, sent the market reeling in a feral pullback. Wha...

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences. ...

Introduction Now that we are in the back half of Q1, I have run out of time to do a full article on every biotech I own, have sold out of, or in other ways have discussed in the past two or so years on Seeking Alpha . So, I would like to provide commentary on several of these stocks, and al...

Nearly 1.8 million Americans were diagnosed with cancer last year. Around the world, the total was close to 17 million. It's not surprising, then, that more than 700 biopharmaceutical companies have experimental cancer drugs in late-stage development. Beta-thalassemia, on the other hand, is a...

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 27, 2020 at 5:00 p.m. EST to discuss its fourth quarter and full year 2019 operating and financial results. The webcast will be accessible under "Events & Presentations...

Biotech has been one of the big winners of this aging bull market. Over the past 10 years, biotech stocks, on balance, have absolutely clobbered the broader U.S. stock markets. The reason is simple: innovation. Through the advent of game-changing molecular, cellular, and genetic technologies, bi...